Volver a la clasificación

Merit Medical Systems, Inc. (MMSI)

NEUTRAL
HealthcareMedical Instruments & SuppliesUnited States

Fundamental

72

Precio

$91.70

Capitalización Bursátil

$5.42B

Parte 1 · Cuánto vale la empresa

Resumen

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems. It also provides custom procedural solutions, including critical care products, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company offers gastroenterology products, such as esophageal stents, cryoballoon and inflation devices, gauges, and balloon dilators; pulmonary products consisting of laser-cut tracheobronchial stents, and over-the-wire and direct visualization delivery systems; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals, alternate site-based physicians, technicians, and nurses through direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers. The company exports its products to Canada, Western Europe, Australia, Brazil, Malaysia, South Korea, the United Arab Emirates, India, New Zealand, and South Africa. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balance y Liquidez

Ingresos

$1.58B

Últimos 12 meses (hasta 30/6/2026)

Beneficio Neto

$146M

Últimos 12 meses (hasta 30/6/2026)

Flujo de Caja Libre

$216M

Patrimonio Neto Total

$1.58B

Pasivo Total

$1.10B

Ratio de Liquidez

4.20

Cobertura de Intereses

6.34

Deuda/EBITDA

2.66

Beneficio Por Acción

Ingresos y Beneficio Neto

Flujo de Caja Libre

Desglose de Ingresos

Estado histórico

Márgenes en el tiempo

La deuda en el tiempo

Cuánto pesa la deuda

Cuadro de crecimiento

Crecimiento — Ingresos

Estimación de Valor Justo

General caseSobrevalorado

Valor Justo

$74.50

Precio Actual

$91.70

Margen de Seguridad

-23.1%

Rango de Valor Justo

$48.43 - $100.58

Métodos de Estimación

Analyst price target:$100.27
Discounted cash flow (DCF):$92.48
Earnings multiple (P/E):$47.60
Graham growth formula:$39.56
Earnings power value (EPV):$33.13
Justified P/B:$31.85
Dividend discount (Gordon):Not enough data to compute it
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$39.47
Revenue multiple:Not enough data to compute it
Consenso de Analistas:Compra Fuerte (14B / 3H / 0S)
Última Sorpresa de Resultados:+21.65%

Métricas de Valoración

Ratio P/E

37.15

ROE

8.1%

Ratio P/B

3.21

P/FCF

26.53

Margen Bruto

49.5%

ROIC

6.1%

Radar de Rentabilidad

Value Creation (Economic Moat)

ROIC

6.1%

WACC

7.3%

ROIC − WACC

-1.2 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Criterios de Análisis Fundamental

Superado (21)

  • EPS shows upward trend
  • EPS CAGR 7.91%
  • Price CAGR 13.10%
  • ROIC 6.1%
  • Gross Margin 49.5%
  • P/FCF 26.53
  • Debt/Equity ratio
  • Operating Margin 12.8%
  • Positive Free Cash Flow
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 9.1%
  • Revenue Growth 5Y 9.5%
  • Analyst Consensus 82% Buy
  • Earnings Surprise avg 11.9%
  • Earnings Quality (OCF/NI) 1.95
  • Share Dilution 1.7%
  • Net Margin Trend 9.2% vs 8.3%
  • Piotroski F-Score 7/9

Fallido (5)

  • P/B Ratio 3.21
  • CapEx intensity
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)

No disponible (2)

  • Dividend Payout NaN%
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

7/9

Solidez financiera fuerte

score
criteria

Calidad de los Beneficios

1.95

Alta calidad: beneficios respaldados por efectivo

Dilución de Acciones

1.7%

El número de acciones es estable

Gobernanza

Equipo Directivo

NombreCargoEdad
Ms. Martha Goldberg AronsonPresident, CEO & Director58
Mr. Raul Parra Jr., CPACFO & Treasurer46
Mr. Brian G. Lloyd J.D.Chief Legal Officer & Corporate Secretary64
Mr. Michel J. VoigtChief Human Resources Officer52
Mr. Jason TreftChief Information Officer-
Ms. Sarah ComstockVice President of Global Communications-
Mr. John KnorppChief Regulatory Affairs Officer-
Mr. Ricardo AlvarezManaging Director of Operation Merit Medical Tijuana-
Mr. Mark ButlerExecutive Vice President of Merit Medical EMEA-
Ms. Alisha JerauldSustainability Council Chair and Vice President of Environment, Social & Governance-

Riesgo de Auditoría

2

Riesgo del Consejo

2

Riesgo de Compensación

1

Riesgo de Derechos del Accionista

4

Parte 2 · El precio y el momento de entrar

Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.

Latest News

Recent headlines for MMSI, sourced from Markets Gazette.

No recent news for MMSI.